Ads
related to: Skyrizi- SKYRIZI® Dosing Info
Learn About The Dosing Frequency Of
SKYRIZI®. See Results For SKYRIZI®.
- SKYRIZI Resources
Skyrizi Complete Offers Resources
To Stay On Track With Treatment.
- Register For More Info
Be The First To Know About
SKYRIZI Info. Sign Up Now.
- After SKYRIZI
See Results From SKYRIZI
For Real Clinical Trial Patients.
- Find a Doctor
Find A Doctor Near You
And Ask About SKYRIZI.
- Support
Find Resources To Help You
Get Started With Treatment.
- SKYRIZI® Dosing Info
Search results
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease
Zacks via Yahoo Finance· 2 years agoThe FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was...
AbbVie (ABBV) Provides Clinical Updates on Inflammatory Drugs
Zacks via Yahoo Finance· 1 year agoAbbVie ABBV announced multiple clinical updates pertaining to clinical studies evaluating its...
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie
Motley Fool· 1 year agoAbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of...
AbbVie Expects Two Of Its Biggest Drugs To Bring In $27 Billion In 2027. And Neither One Is Humira.
Investor's Business Daily· 3 months agoAbbVie expects its burgeoning immunology drugs, Skyrizi and Rinvoq, to top $27 billion in 2027...
These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy
Motley Fool via Yahoo Finance· 3 months agoThere are thousands of drugs on the market, and there are thousands more that are no longer in use....
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
Reuters via AOL· 3 months ago(Reuters) -AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and...
AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales
Investor's Business Daily· 2 weeks agoFears that Humira biosimilars will erode AbbVie's top line are overblown, an analyst said Monday as...
AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales
Zacks via Yahoo Finance· 1 year agoAbbVie Inc. ABBV reported adjusted earnings of $3.60 per share for the fourth quarter of 2022,...
AbbVie's Blockbuster Is Falling Fast. Time to Sell?
Motley Fool· 1 year agoLast week wasn't a great one for a lot of pharmaceutical stock investors. Shares of AbbVie (NYSE: ABBV) dropped by about 8% on Thursday, April 27. The...
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 3 weeks agoAbbVie ABBV will report first-quarter 2024 results on Apr 26, before market open. In the last...
Ads
related to: Skyrizi